hrp0094p2-256 | Growth hormone and IGFs | ESPE2021

Thyroid function (TF) in short children with idiopathic short stature (ISS) treated with growth hormone (GH)versus those not treated; a controlled study.

Elsiddig Sohair , Soliman Ashraf , Alaaraj Nada , Khalil Ahmed , Ahmed Hannah ,

In ISS is a condition with a height is >2SD below the corresponding mean for age, sex, and population. Thyroid abnormalities reported during GH therapy in GH deficient (GHD) children but not well studied in ISS children on GH therapy.Aim: To investigate effects of GH therapy on TF in a group of euthyroid children with ISS in comparison with ISS group not receiving GH therapy and GHD group on GH therapy.Material...

hrp0094p2-264 | Growth hormone and IGFs | ESPE2021

Growth hormone (GH) treatment of children with idiopathic short children (ISS) with normal insulin-like growth factor-1 (IGF-1) versus those with low IGF-I at diagnosis.

Elsiddig Sohair , Soliman Ashraf , Alaaraj Nada , Khalil Ahmed , Ahmed Hannah ,

ISS is a condition in which the height is more than 2 SD below the corresponding mean height for age, sex and population, in whom no identifiable disorder is present. Some ISS patients may have varying degrees of IGF-1 deficiency. Recombinant GH treatment has been used by some authors with variable results. Theoretically, low IGF-I level at presentation may affect their response to GH therapy. The question is: do children with ISS and low IGF-I respond differently to GH therap...

hrp0094p2-265 | Growth hormone and IGFs | ESPE2021

Growth response to growth hormone therapy in growth hormone deficient (GHD) children in relation to the distance between their height SDS (HtSDS) and their mid-parental height.

Elsiddig Sohair , Soliman Ashraf , Alaaraj Nada , Khalil Ahmed , Ahmed Hannah ,

Introduction: Mid-parental height (MPH) is a useful tool in the prediction of final adult height in normal children as well as those on growth hormone (GH) therapy. Aim of the study to evaluate the growth response to GH therapy in GHD children in relation to their MPH.Methods: This retrospective study included 22 short prepubertal children with GHD (peak GH<10 μg/l). They were followed in the Endocrine clinic be...

hrp0094p2-266 | Growth hormone and IGFs | ESPE2021

Linear growth and response to GH therapy in children with short stature with normal Growth hormone secretion: Comparison between children with delayed versus no delay in the bone age at diagnosis.

Elsiddig Sohair , Soliman Ashraf , Alaaraj Nada , khalil Ahmed , Ahmed Hannah ,

Bone age (BA) continues to be a valuable tool in assessing children’s growth potential. Children with normal variant short stature can be subdivided into idiopathic short stature (ISS) (with no delay in BA versus chronological age (CA) and constitutional delay (CDG) (with delayed BA versus CA. The response of these two groups to GH therapy remains controversial.Aim, patients, and methods: We studied linear growth, weight gain, skeletal maturation, a...

hrp0094p2-267 | Growth hormone and IGFs | ESPE2021

Linear growth and response to GH therapy in children with GHD with normal IGF-I versus those with normal GH secretion associated with low IGFI at presentation.

Elsiddig Sohair , Soliman Ashraf , Khalil Ahmed , Alaaraj Nada , Ahmed Hannah ,

Introduction: Children with idiopathic short stature have linear growth impairment despite normal or even high levels of GH. In some of these children IGFI level is low (NGH + Low IGFI (IGFSDS<-1.5). It was observed that some children with GHD (Peak GH < 7 ng/dl after provocation) have normal IGFI levels (GHD +Normal IGFI). The linear growth of these two groups at presentation and their response to GH therapy was not studied well.<p class="abstext"...

hrp0094p2-268 | Growth hormone and IGFs | ESPE2021

Growth response to growth hormone therapy in short children in relation to their distance from mid-parental heights (MPHt).

Elsiddig Sohair , Soliman Ashraf , Alaaraj Nada , Khalil Ahmed , Ahmed Hannah ,

In normal children, mid parental height (MPH) is a useful tool in assessing children’s growth and in the prediction of their final adult height. However, this may not be true for short children, especially those with height SD (HtSDS) > - 1SDS compared to their mid-parental height SDS (MPHtSDS). The difference may indicate underlying pathology.Aim: To assess growth response (change in HtSDS) to GH therapy in short prepubertal ch...

hrp0097p1-161 | Pituitary, Neuroendocrinology and Puberty | ESPE2023

Quality of life domains changes in children with central precocious puberty

Raafat Shaimaa , Mowafy Ehsan , Abdelaal Esraa , Khalil Mona

Background: Precocious puberty is considered a stressful condition leading to psychosocial and behavioral problems in children. Many factors are involved in these changes such as early body changes which make them feeling strange and cause the sense of isolation from social groups. On the other hand, GnRHa treatment can affect psychological functioning of children with CPP through several pathways. There is controversy in the results of studies dealing with th...

hrp0092p3-160 | Growth and Syndromes (to include Turner Syndrome) | ESPE2019

Thyroid Dysfunction in the First Year of Life in Infants with Down syndrome: Linear Growth Over 4 Years

Alaaraj Nada , Soliman Ashraf , Itani Maya , Mohamed Shayma , Khalil Ahmed , adel ashraf

Background: Down syndrome (DS) is associated with thyroid dysfunction including both congenital and acquired hypothyroidism (HT) However, data about thyroid function in infants < 1 year with DS is scarce.The aim of this study was to investigate the prevalence of different thyroid dysfunctions in a cohort of infants with DS (n = 47) (22 M, 25 F) and follow up their linear growth and weight gain for an average of 4 years.<p cla...

hrp0095p2-91 | Diabetes and Insulin | ESPE2022

Presentation of Newly Diagnosed Type1 Diabetes Mellitus

Khan Khalid

Children with early signs and symptoms of Type 1 Diabetes need to be diagnosed promptly, before they become acutely unwell with diabetic ketoacidosis (DKA). Early diagnosis and optimal management of established DKA is key to reducing morbidity and mortality. To follow the evidence based standards. To assess whether the newly diagnosed type 1 diabetes were in DKA at presentation or not. To assess compliance to guidelines on admission. As per retrospective cohort study, charts o...

hrp0089p3-p016 | Adrenals and HPA Axis P3 | ESPE2018

Adrenals and HPA Axisa; Atypical Presentation of Adrenal Insufficiency

Khan Khalid

Case report: Atypical presentation of adrenal insufficiency: 13 year old presented with vomiting (one day), lethargy two weeks. mild dehydration, vitals stable, generally healthy, examination unremarkable, medication nill, history of insect bite two weeks ago, no allergies, started on I. V maintenance fluids, investigations (blood) normal, the only abnormal was low soduim, normal glucose and potassium, soduim was 122 mol/l, repeated soduim was 119 after the maintain ace 0.9% n...